EUVIMEDEUVIMED entdecken
Crossref

Spleen-Targeted mRNA Vaccine Doped with Manganese Adjuvant for Robust Anticancer Immunity In Vivo

Zijin Luo, Yi Lin, Yanan Meng, Mengyao Li, Hongyu Ren, Haoping Shi, Qiang Cheng iD, Tuo Wei iD

ACS Nano · 05.11.2024 · 18 (44) · 30701-30715

DOI: 10.1021/acsnano.4c09902 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, online erschienen am 28.10.2024. Verfasst von Zijin Luo und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China. Hauptthemen laut MEDLINE: Manganese, Spleen, Adjuvants, Immunologic, Cancer Vaccines. Die Arbeit wurde bisher 94-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Key Research and Development Program of China, China Postdoctoral Science Foundation, Natural Science Foundation of Beijing Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The successful application of mRNA vaccines in preventing and treating infectious diseases highlights their potential as therapeutic vaccines for cancer treatment. However, unlike infectious diseases, effective antitumor therapy, particularly for solid tumors, necessitates the activation of more powerful cellular and humoral immunity to achieve clinical efficacy. Here, we report a spleen-targeted mRNA vaccine (Mn@mRNA-LNP) designed to deliver tumor antigen-encoding mRNA and manganese adjuvant (Mn2+) simultaneously to dendritic cells (DCs) in the spleen. This delivery system promotes DC maturation and surface antigen presentation and stimulates the production of cytotoxic T cells. Additionally, Mn2+ codelivered in the system serves as a safe and effective immune adjuvant, activating the stimulator of interferon genes (STING) signaling pathway and promoting the secretion of type I interferon, further enhancing the antigen-specific T cell responses. Mn@mRNA-LNP effectively inhibits tumor progression in established melanoma and colon tumor models as well as in a model of tumor recurrence after resection. Notably, the combination of Mn@mRNA-LNP with immune checkpoint inhibitors further enhances complete tumor suppression and prolonged the overall survival in mice. Overall, this "All-in-One" mRNA vaccine significantly boosts antitumor immunity responses by improving spleen targeting and immune activation, providing an attractive strategy for the future clinical translation of therapeutic mRNA vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ManganeseSpleenAdjuvants, ImmunologicCancer VaccinesMice, Inbred C57BLmRNA VaccinesAnimalsMiceDendritic CellsFemaleRNA, MessengerCell Line, TumorAntigens, Neoplasm

Stichwörter der Autor:innen

STINGantigen-specific T cellmRNA vaccinesmanganese adjuvantspleen-targetingtype I interferon

Substanzen

ManganeseAdjuvants, ImmunologicCancer VaccinesmRNA VaccinesRNA, MessengerAntigens, Neoplasm

Autor:innen und Institutionen

  • State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China.
  • Key Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China.
  • Beijing Institute for Stem Cell and Regenerative Medicine, Beijing 100101, China.
  • University of Chinese Academy of Sciences, Beijing 100049, China.
  • Department of Biomedical Engineering, College of Future Technology, Peking University, Beijing 100871, China.
  • Beijing Advanced Center of RNA Biology, Peking University, Beijing 100871, China.

ORCID-Profile: Qiang Cheng, Tuo Wei

Förderung

  • National Key Research and Development Program of China
  • China Postdoctoral Science Foundation
  • Natural Science Foundation of Beijing Municipality
  • National Natural Science Foundation of China
  • Chinese Academy of Sciences
  • Beijing Institute for Stem Cell and Regenerative Medicine
  • Beijing-Tianjin-Hebei Basic Research Cooperation Project
  • Key Technology Program for Nucleic Acid Drugs of NCTIB

Zitieren

APA

Luo, Z., Lin, Y., Meng, Y., Li, M., Ren, H., Shi, H., Cheng, Q., & Wei, T. (2024). Spleen-Targeted mRNA Vaccine Doped with Manganese Adjuvant for Robust Anticancer Immunity In Vivo. ACS Nano, 18(44), 30701-30715. https://doi.org/10.1021/acsnano.4c09902

Vancouver

Luo Z, Lin Y, Meng Y, Li M, Ren H, Shi H, et al. Spleen-Targeted mRNA Vaccine Doped with Manganese Adjuvant for Robust Anticancer Immunity In Vivo. ACS Nano. 2024;18(44):30701-30715. doi:10.1021/acsnano.4c09902

BibTeX
@article{Luo2024,
  author = {Luo, Zijin and Lin, Yi and Meng, Yanan and Li, Mengyao and Ren, Hongyu and Shi, Haoping and Cheng, Qiang and Wei, Tuo},
  title = {Spleen-Targeted mRNA Vaccine Doped with Manganese Adjuvant for Robust Anticancer Immunity In Vivo},
  journal = {ACS Nano},
  year = {2024},
  volume = {18},
  number = {44},
  pages = {30701--30715},
  doi = {10.1021/acsnano.4c09902}
}
Kostenlos starten →